Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 4
4(100.0%)
4Total
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06016231Completed

Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye

Role: lead

NCT04120987Phase 4Withdrawn

Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

Role: lead

NCT05610540Completed

Patient Preference and Visual Quality With Contralateral Synergy Versus Panoptix

Role: lead

NCT04134507Completed

Patient Satisfaction in Post-LASIK Patients With Presbyopia-Correcting IOLs vs. Post-Lasik Patients With Monofocal IOLs

Role: lead

NCT01296542Phase 4Completed

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

Role: lead

NCT01091714Phase 4Completed

Is Omega-3 Fatty Acid Red Blood Cell (RBC) Saturation Product Dependent?

Role: lead

NCT01023724Phase 4Completed

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Role: lead

All 7 trials loaded